Affordable World-class Treatment - Accredited Hospitals - Free Treatment Plan in 24 Hrs
Share your details to receive a personalised treatment plan, estimated costs, hospital recommendations, and expert guidance, “completely free.”
Your information is protected with HIPAA-compliant security standards. We only share your details with hospitals after your consent.
| City | Cost (USD) | |
|---|---|---|
| Kaunas | $300,000 – $500,000 | Explore More |
| Vilnius | $300,000 – $500,000 | Explore More |
Alvina Hasan is a dedicated medical researcher and scientific writer with a strong foundation in pharmaceutical sciences. She holds a B.Pharm from Jamia Hamdard University and an M.Pharm in Quality Assurance from DIPSAR University.
With deep medical expertise and a strong interest in healthcare communication, she focuses on transforming complex clinical and scientific information into clear, engaging, and easy-to-understand narratives. She develops insightful healthcare articles and research-driven content designed to support both medical professionals and patients, helping bridge the gap between advanced medical knowledge and practical understanding.
Readers can explore her published research and articles here:
Our dedicated Medical Patient Advisors are here to answer your questions, help you compare treatment options, estimate costs, and guide you through every step of your healthcare journey.
CAR T-cell therapy represents a groundbreaking approach to harnessing the power of the body's immune system to combat cancer. By modifying T cells, a subset of white blood cells, in a laboratory setting, these cells are empowered to recognize and eliminate cancer cells with precision. Often categorized as a form of cell-based gene therapy, CAR T-cell therapy involves altering the genetic makeup of T cells, equipping them with the ability to target specific cancer antigens.
This innovative treatment has demonstrated remarkable efficacy, particularly in cases where conventional therapies have proven ineffective. Its ability to reprogram the immune system to target and destroy cancer cells marks a significant advancement in cancer treatment strategies.
CAR T cell therapy is classified as follows:
Antigen-based classification: It includes
CAR T-cell therapy is primarily used to treat blood cancers, such as multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukaemia. The patient's own T cells are reprogrammed to identify and destroy cancer cells, cause remission, enhance survival, and have a plan B in case other treatments fail.
Patients with blood cancers who relapsed or are refractory must consult an oncologist to determine candidacy for CAR T therapy, especially if they have failed to respond to traditional treatments (i.e., chemotherapy, radiation, or stem cell transplant). Evaluation is warranted for symptoms such as loss of weight, swelling of lymph nodes, recurrent infection, chronic fatigue, or spontaneous bruising.
Screening tests consist of imaging, bone marrow biopsy, and blood work.
Leukapheresis is utilised to harvest T cells from the patient's blood for T-cell collection.
Bridging therapy: Certain patients receive chemotherapy while waiting for CAR T cells to be produced.
Lymphodepleting chemotherapy is administered before the injection to make room for CAR T cells. The patients should plan for potential hospitalisation, designate caretakers, and discuss long-term follow-up and expected adverse effects with the medical team.
The whole process, from cell harvesting to infusion, can take three to six weeks. The infusion itself takes a few hours to a few minutes, but for at least one week following the infusion, close monitoring is required, and there will be frequent follow-ups for several months.
One of the newer treatment options for some blood cancers is CAR T-cell therapy. It is utilised when other treatments are not working or the cancer recurs. CAR T-cell therapy has the potential to cure many blood cancers and extend life in most cases.
Recovery involves managing side effects like CRS and neurotoxicity, monitoring blood levels, and avoiding infections. Laboratory testing, imaging, and monitoring for late issues like hypogammaglobulinemia or relapse are all included in long-term follow-up.
The nature of the cancer, the burden of the disease, and an individual's response all impact success. For example, in pediatric acute lymphoblastic leukaemia, complete remission rates are more than 80%. However, relapse is always a risk, and long-term success is variable.
80%
Complete remission (pediatric ALL)2 days
in hospital post-infusion3 Months
to typical return to workOur experienced Medical Patient Advisors have supported 100,000+ patients across 120+ countries with personalised treatment plans, hospital recommendations, cost estimates, and travel assistance, all free.
✓ Free Consultation ✓ No Obligation ✓ Personalized Treatment Plan ✓ Response Within 24 Hours
Your medical info is kept HIPAA-style confidential. We never share with hospitals without your consent.
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Hendrik decided to come to India for his treatment after a thorough discussion with MediGence. India is known for its…
CAR-T package cost in Vilnius has different inclusions and exclusions. The CAR-T package cost usually includes all the expenses related to pre and post surgery expenses of the patient. The CAR-T cost in Vilnius includes the cost of anesthesia, medicines, hospitalization and the surgeon's fee. Post-surgical complications, new findings and delayed recovery may have an impact on the total CAR-T cost in Vilnius.
There are many hospitals that perform CAR-T in Vilnius. The top hospitals for CAR-T in Vilnius include the following:
After CAR-T in Vilnius, the patient is supposed to stay in guest house for another 28 days. This time frame is important to ensure that the surgery was successful and the patient is fit to fly back.
Vilnius is one of the most popular cities for CAR-T in the world. The country offers the best cost of CAR-T, best doctors, and advanced hospital infrastructure. However, some of the other popular destinations for CAR-T include the following:
There are certain additional cost that the patient has to pay apart from the CAR-T cost. The per day extra expenses in Vilnius per person are about 50 USD.
It is possible for patients to opt for video telemedicine consultation before they come for CAR-T in Vilnius. Some of the surgeons offering this service include the following:
Some of the most sought after doctors available for online video consultation for CAR-T in Vilnius are:
| Doctor Name | Cost | Book Appointment |
|---|---|---|
| Dr. Valerijus Ostapenko | 300 | Book Now |
| Dr. Rimantas Bausys | 140 | Book Now |
The average duration of stay at the hospital after CAR-T is about 2 Days for proper care and monitoring. The doctors team review the patient's recovery during this time with the help of blood tests and imaging scans. Once they feel that everything is on track, the patient is discharged.
Out of all the hospitals in Vilnius, there are about 1 Hospitals best hospitals for CAR-T in Vilnius. These hospitals are approved to perform the surgery and have proper infrastructure to handle CAR-T patients. These hospitals comply with all the rules and regulations as dictated by the regulatory bodies and medical association in Vilnius
Have your reports reviewed by independent oncology experts to help you make a confident treatment decision, all online within 48 hours.
Upload Your Reports
